XORTX Therapeutics Inc
XTSX:XRTX

Watchlist Manager
XORTX Therapeutics Inc Logo
XORTX Therapeutics Inc
XTSX:XRTX
Watchlist
Price: 0.72 CAD -6.49%
Market Cap: CA$5m

Net Margin

0%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
CA$0
/
$0

Peer Comparison

Country Company Market Cap Net
Margin
CA
XORTX Therapeutics Inc
XTSX:XRTX
5m CAD
Loading...
US
Eli Lilly and Co
NYSE:LLY
996.6B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
540.6B USD
Loading...
CH
Roche Holding AG
SIX:ROG
278.2B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
216.3B GBP
Loading...
CH
Novartis AG
SIX:NOVN
223.2B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
267.2B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
150.4B USD
Loading...
FR
Sanofi SA
PAR:SAN
97.1B EUR
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

XORTX Therapeutics Inc
Glance View

Market Cap
5m CAD
Industry
Pharmaceuticals

XORTX Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-09-30. The firm is focused on identifying, developing and commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD) and type 2 diabetic nephropathy (T2DN) as well as acute kidney injury (AKI) due to coronavirus infection. Its lead product candidates are XRx-008, XRx-101 and XRx-225. XRx-008 is a late clinical stage program focused on demonstrating the potential of its therapy for ADPKD. XRx-101 is a program to treat acute kidney injury associated with Coronavirus/ COVID-19 infection, AKI and associated health consequences. XRx-225 is a program for the treatment of T2DN. The company is also working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid.

XRTX Intrinsic Value
0.72 CAD
Fairly Valued
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Back to Top